Valuation: Evaxion A/S

Market Cap 27.94M 23.94M 22.43M 20.49M 38.67M 2.66B 39.05M 265M 103M 1.34B 105M 103M 4.45B P/E 2026 *
-83.8x
P/E 2027 * -223x
Enterprise Value 27.94M 23.94M 22.43M 20.49M 38.67M 2.66B 39.05M 265M 103M 1.34B 105M 103M 4.45B EV / Sales 2026 *
-
EV / Sales 2027 * 5.98x
Free-Float
76.93%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+6.35%
Current month+18.79%
1 month+13.18%
3 months-17.89%
6 months-0.59%
Current year-29.77%
1 week 2.95
Extreme 2.95
3.64
1 month 2.77
Extreme 2.77
3.64
Current year 2.77
Extreme 2.77
5.48
1 year 2.52
Extreme 2.52
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 2025-11-23
Corporate Officer/Principal 49 2008-08-10
Director of Finance/CFO 53 2024-10-31
Director TitleAgeSince
Chairman 58 2020-11-24
Director/Board Member 56 2017-12-31
Director/Board Member 68 2021-05-24
Date Insider Type Main position Quantity % Market Cap.
3/18/26 Other

Chief Financial Officer

968,600 0.2323%
3/18/26 Other

Chairman

6,473,997 1.5525%
3/18/26 Other

Director

1,171,030 0.2808%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+6.35%+4.49%-92.56% 28.36M
+1.02%+4.95%+3.67%+25.46% 51.21B
-0.09%-2.14%+492.60%+537.84% 45.35B
-0.32%+8.08%+37.97%+18.45% 42.84B
+1.18%+1.96%+21.95%+89.69% 42.29B
-2.27%-3.02%+14.22%+51.50% 32.15B
-0.96%+4.03%+31.55%+136.34% 17.31B
+0.41%+1.66% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
-0.31%+6.61%+81.37%+48.53% 14.25B
Average -0.18%+3.61%+77.65%+94.21% 27.68B
Weighted average by Cap. +0.02%+2.85%+105.31%+136.27%

Financials

2026 *2027 *
Net sales - 4.67M 4M 3.75M 3.43M 6.46M 445M 6.53M 44.23M 17.22M 225M 17.54M 17.15M 744M
Net income -15.63M -13.39M -12.55M -11.46M -21.63M -1.49B -21.85M -148M -57.62M -752M -58.68M -57.4M -2.49B -11.86M -10.16M -9.52M -8.7M -16.41M -1.13B -16.57M -112M -43.71M -570M -44.52M -43.55M -1.89B
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
26-08-25 US$3.350 -1.47% 148,842
26-08-24 US$3.400 +2.72% 183,587
26-08-21 US$3.310 +0.91% 540,831
26-08-20 US$3.280 +4.13% 3,595,126
26-08-19 US$3.150 0.00% 6,361,783
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.350USD
Average target price
11.25USD
Spread / Average Target
+235.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock